New drug combination for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination therapy for extensive-stage small cell lung cancer (cancer that has spread beyond the lung). The treatment includes an immunotherapy drug, a drug that blocks blood vessel growth to tumors, and chemotherapy. It aims to see how well this combination works in people who have not yet been treated for this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (cancer that has spread beyond one lung and nearby lymph nodes).
- You have not received any previous treatment for your lung cancer.
- You are 18 years or older.
- You are able to take care of yourself (able to walk and carry on daily activities, even if you may need some help).
- You have at least one tumor that can be measured by scans.
- Your blood counts, liver, and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a new combination of two drugs (QLC5508 and QL2107) compared to the standard treatment (tislelizumab plus chemotherapy) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the new combination works better at controlling the cancer.
This trial tests a new drug (QL1706) combined with bevacizumab, with or without chemotherapy, for people with advanced non-squamous non-small cell lung cancer that has grown after prior immunotherapy. It aims to see if this combination can help control the cancer.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
Hear when a new Extensive Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.